Dimensional Fund Advisors LP Raises Holdings in Voyager Therapeutics, Inc. (NASDAQ:VYGR)

Dimensional Fund Advisors LP boosted its position in Voyager Therapeutics, Inc. (NASDAQ:VYGR - Free Report) by 24.9% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,380,615 shares of the company's stock after purchasing an additional 275,571 shares during the quarter. Dimensional Fund Advisors LP owned approximately 2.53% of Voyager Therapeutics worth $7,828,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. Picton Mahoney Asset Management raised its holdings in Voyager Therapeutics by 71.1% in the fourth quarter. Picton Mahoney Asset Management now owns 5,883 shares of the company's stock worth $33,000 after purchasing an additional 2,444 shares in the last quarter. Virtu Financial LLC bought a new stake in Voyager Therapeutics in the 4th quarter worth about $100,000. Legal & General Group Plc increased its holdings in Voyager Therapeutics by 65.2% in the 4th quarter. Legal & General Group Plc now owns 19,245 shares of the company's stock worth $109,000 after buying an additional 7,597 shares in the last quarter. SG Americas Securities LLC increased its holdings in Voyager Therapeutics by 86.7% in the 4th quarter. SG Americas Securities LLC now owns 23,044 shares of the company's stock worth $131,000 after buying an additional 10,704 shares in the last quarter. Finally, XTX Topco Ltd bought a new stake in Voyager Therapeutics in the 4th quarter worth about $178,000. Institutional investors own 48.03% of the company's stock.

Insiders Place Their Bets

In other Voyager Therapeutics news, CEO Alfred Sandrock sold 10,885 shares of the company's stock in a transaction on Wednesday, April 2nd. The stock was sold at an average price of $3.43, for a total value of $37,335.55. Following the completion of the sale, the chief executive officer now directly owns 430,931 shares in the company, valued at approximately $1,478,093.33. This represents a 2.46% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 6.39% of the company's stock.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on the company. Cantor Fitzgerald reissued an "overweight" rating on shares of Voyager Therapeutics in a research report on Wednesday, March 12th. HC Wainwright reissued a "buy" rating and issued a $30.00 target price on shares of Voyager Therapeutics in a research report on Tuesday, April 8th. Wells Fargo & Company set a $10.00 target price on Voyager Therapeutics and gave the stock an "overweight" rating in a research report on Wednesday, March 12th. Canaccord Genuity Group dropped their target price on Voyager Therapeutics from $14.00 to $12.00 and set a "buy" rating on the stock in a research report on Thursday, March 13th. Finally, Wedbush reaffirmed an "outperform" rating on shares of Voyager Therapeutics in a research report on Wednesday, March 12th. One analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus target price of $13.39.

Voyager Therapeutics Stock Up 0.2%

VYGR traded up $0.01 during trading hours on Friday, reaching $3.29. 67,217 shares of the company's stock traded hands, compared to its average volume of 361,769. The firm has a 50-day moving average price of $3.45 and a 200 day moving average price of $4.84. Voyager Therapeutics, Inc. has a 52-week low of $2.75 and a 52-week high of $9.55. The firm has a market capitalization of $181.78 million, a PE ratio of 4.63 and a beta of 0.95.

Voyager Therapeutics (NASDAQ:VYGR - Get Free Report) last issued its earnings results on Tuesday, May 6th. The company reported ($0.53) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.18). Voyager Therapeutics had a return on equity of 8.33% and a net margin of 15.80%. The firm had revenue of $6.47 million during the quarter, compared to analysts' expectations of $13.55 million. Equities analysts predict that Voyager Therapeutics, Inc. will post -0.91 EPS for the current fiscal year.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.